A list is being prepared to vaccinate children between the ages of 12 and 1 against Kovid-1, and details will be released before the Zidas Cadila vaccine – the first vaccine given to children – is launched in October. Vaccination advisory group said. Citing the Sero survey, Dr NK Aurora, head of the National Technical Advisory Group on NTGI, said it was highly unlikely that children would face serious health complications due to the virus, as he suggested reopening the school, which he said was necessary for children’s “intellectual development”. .
“There are 120 million children between the ages of 12 and 17. They are less likely to have serious health complications or death due to the virus. Hall vaccinated this group under the National Immunization Campaign before vaccinating children, ”said Dr Aurora.
He said there are about 1 billion children under the age of 14 in the country, but added that children are only victims of mild infections.
“According to the Sero survey, children are infected, but the chances of serious health complications or death were very low. Children can go to school. There is no need to be vaccinated. Vaccinated, ”he said.
Dr Aurora’s comments came amid fears that the third wave could affect children more than adults. “The National Institute of Disaster Management (NIDM), run under the Ministry of Home Affairs, has indicated,‘ Pediatric facilities – doctors and equipment, such as ventilators and ambulances, are nowhere near the need. “, As part of the report recommending preparations for the third wave.
ZyCoV-D, the world’s first indigenously developed DNA-based needle-free Covid-1 vaccine, was approved for emergency use on August 20. It will be the first vaccine given to adults in the country between the ages of 12-1 years.
The Department of Biotechnology (DBT) states that when injected, ZyCoV-D produces spike proteins of the SARS-CoV-2 virus and builds immunity, which plays an important role in protecting against disease as well as viral clearance.
It said that the interim results of the third phase of clinical trials among more than 2,000 Phase 2 volunteers showed an initial efficacy of 66.6 per cent in RT-PCR positive cases. This is the largest vaccine trial to date for Covid-1 for in India, according to DBT.
The vaccine has already demonstrated strong immunogenicity and tolerance and safety profiles in adaptive one and two clinical trials. It said that both the one / two and third stage clinical trials have been monitored by an independent data safety monitoring board.